Appetite News and Research

RSS

Why exercise matters for obesity even when the scale barely moves

AHA's scientific statement reveals exercise's vital role in obesity management, boosting cardiovascular health and supporting long-term weight loss efforts.

4 Jun 2026

Brain-body interactions during hunger make imagined food especially tempting

We are often told not to go to the supermarket on an empty stomach.

3 Jun 2026

GLP-1 medications linked to lower breast cancer risk in women

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.

2 Jun 2026

Weight loss drugs could widen health inequalities without nutritional support

Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without affordable, healthy food and appropriate support, they could widen health inequalities in the UK, according to researchers at UCL and the University of Cambridge.

1 Jun 2026

Fruit fly study links dopamine to stress-induced sexual dysfunction

Scientists from Tokyo Metropolitan University have revealed key parts of the biochemical pathways connecting stress to sexual dysfunction.

30 May 2026

Ghrelin rises in depression despite obesity’s usual appetite-hormone suppression

Researchers found that both acylated and deacylated ghrelin were elevated in unmedicated adults with major depressive disorder and obesity compared with non-depressed adults with obesity. The cross-sectional findings suggest ghrelin-system dysregulation may be linked to depression in obesity, but larger longitudinal studies are needed to test whether ghrelin is a reliable biomarker.

27 May 2026

Ongoing nausea in pregnancy may flag anxiety and depression risk

Persistent or severe nausea during pregnancy was linked to higher maternal anxiety and depressive symptoms across gestation. The study found little consistent evidence that nausea worsened most perinatal outcomes, suggesting it may serve mainly as a clinical warning sign for psychological burden.

25 May 2026

Targeting lipid enzymes triggers starvation states in aggressive tumor cells

While many American adults are trying to reduce cholesterol levels, certain cancerous tumors have a relentless appetite for the metabolite.

22 May 2026

Semaglutide helps patients who gain weight after bariatric surgery

New UCL research supports use of the weight loss drug semaglutide for patients who do not get enough benefit from bariatric surgery.

22 May 2026

NIH researchers discover how weight-loss drugs alter brain cells

A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events GLP-1 receptor agonists trigger within neurons, which have been largely unexplored until now.

22 May 2026

GLP-1 drugs may help curb addiction by targeting reward pathways

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways. Most evidence remains preclinical, with limited early human data, so larger clinical trials are needed before these drugs can be recommended for addiction treatment.

21 May 2026

Azithromycin fails to improve severe wheezing in preschool children

A study led by researchers at the University of Arizona College of Medicine – Tucson showed that giving the antibiotic azithromycin did not help preschool children seen in the hospital emergency room with bouts of severe wheezing.

18 May 2026

Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss

A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.

15 May 2026

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

Cannabis compounds may improve metabolism and reduce diabetes risk

A University of California, Riverside preclinical study is shedding light on a long-observed but poorly understood phenomenon: chronic cannabis users tend to have lower body weight and a reduced risk of developing type 2 diabetes, despite the drug's well-known tendency to increase appetite.

11 May 2026

Gene mapping highlights strong immune and brain connections in depression

Neurons and white blood cells differ greatly in shape, function, and location within the body. However, researchers at the University of São Paulo (USP) in Brazil discovered that certain genes are equally dysregulated in both cell types in people with depression.

11 May 2026

Diabetes, weight-loss drugs not a perfect fit?

Type 2 diabetes affects millions of people worldwide and now a new international study, jointly led by Adelaide University, University of Oxford, ETH Zurich, and Stanford University, has found one in ten people may not be benefiting from common medications used to treat the condition.

11 May 2026